To the mitochondrial disease community, As I wrap up my first full week as United Mitochondrial Disease Foundation (UMDF) President and...
Read: A Special Message from New UMDF President & CEO Kristen CliffordThe United Mitochondrial Disease Foundation (UMDF) Board of Trustees has named Kristen Clifford the organization’s next President and Chief...
Read: United Mitochondrial Disease Foundation Names Kristen Clifford New President & CEOSign-up to receive the UMDF newsletter via email at Newsletter Signup. Mitochondrial Medicine 2025Call For Abstracts Now OpenUMDF's Call...
Read: January 2025 Newsletter: Mito Med 2025 News, Advocacy Update, CPEO & MELAS Webcasts, and MoreSign-up to receive the UMDF newsletter via email at Newsletter Signup. The Mito Fund Announces Investment in Khondrion UMDF’s venture...
Read: December 2024 Newsletter: Mito Fund Investment, Mito Med 2025 News, Clinical Trial Updates, and MoreWith the recent election results, we’ve been getting some inquiries about the impact of a second Trump Administration on mitochondrial disease...
Read: UMDF November Advocacy Update: What Does a Second Trump Administration Mean for the Mito Community?The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based...
Read: The Mito Fund Announces Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial DiseaseUMDF Cosigns Letter to Congress Encouraging End-of-Year Action on Accelerating Kids’ Access to Care Act, Rare Pediatric Disease Priority Review...
Read: UMDF Cosigns Letter to Congress Encouraging End-of-Year Rare Disease Legislative PrioritiesSign-up to receive the UMDF newsletter via email at Newsletter Signup. In early October, an FDA Advisory Committee voted 10-6 supporting...
Read: November 2024 Newsletter: FDA News, Rare Revolution Magazine Feature, Therapeutic Pipeline Updates, and moreFDA Advisory Committee Deems Potential Barth Syndrome Drug “Effective” Earlier this month, an FDA Advisory Committee voted 10-6...
Read: Advocacy Update – Oct 2024: FDA AdComm Brings Good News, Plus DC End of Year Business